Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab
- Development stage
- Approved
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma and some other malignant cells. By binding to CD38, daratumumab induces cell death through several immune-mediated mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). It also modulates the immune response by depleting immunosuppressive cells expressing CD38. Daratumumab is primarily indicated for the treatment of multiple myeloma as monotherapy or in combination with other agents, and it is also approved for light chain (AL) amyloidosis in combination regimens. The drug was developed by Janssen and Genmab.
- Brand names
- DarzalexDarzalex Faspro
- Other names
- Humanised anti-CD38 monoclonal antibodyHuMax-CD38HuMax-CD-38HuMax-CD 38
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab.